Michael Horowitz
Overview
Explore the profile of Michael Horowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
564
Citations
10245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamruzzaman M, Horowitz M, Rahman M, Deshmukh H, Jones K, Marathe C
J Diabetes Investig
. 2025 Mar;
PMID: 40083113
Background: Food insecurity (FIS) affects around 25% of Bangladesh's population, and data from developed nations report higher FIS rates among individuals with type 2 diabetes (T2D), potentially worsening glycemic control....
2.
Anjom-Shoae J, Hajishafiee M, Fitzgerald P, Coleman R, Martin A, Poppitt S, et al.
Am J Clin Nutr
. 2025 Feb;
PMID: 39978467
Background: L-tryptophan ("Trp") and L-leucine ("Leu"), when administered intraduodenally, increase plasma cholecystokinin (CCK) and glucagon-like peptide 1 (GLP-1) and stimulate pyloric pressures, which all slow gastric emptying and suppress subsequent...
3.
Anjom-Shoae J, Fitzgerald P, Horowitz M, Holst J, Rehfeld J, Veedfald S, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39785828
Context: In males of normal weight, intraduodenal administration of calcium enhances the effects of the amino acid, L-tryptophan (Trp), to suppress energy intake, associated with greater stimulation of cholecystokinin (CCK),...
4.
Quast D, Xie C, Bound M, Grivell J, Hatzinikolas S, Jones K, et al.
Diabetes
. 2025 Jan;
PMID: 39761379
Individuals with type 2 diabetes are at high risk of postprandial falls in blood pressure (BP) (i.e., a reduction in systolic BP of ≥20mmHg, termed postprandial hypotension (PPH)), which increases...
5.
Xie C, Iroga P, Bound M, Grivell J, Huang W, Jones K, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1614-1617.
PMID: 39727162
No abstract available.
6.
Bitarafan V, Anjom-Shoae J, Rezaie P, Fitzgerald P, Lange K, Horowitz M, et al.
Diabetologia
. 2024 Dec;
PMID: 39690248
Aims/hypothesis: Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy...
7.
Stretton B, Booth A, Kovoor J, Gupta A, Edwards S, Hugh T, et al.
Age Ageing
. 2024 Dec;
53(12).
PMID: 39656763
Background: Frailty, malnutrition and low socioeconomic status may mutually perpetuate each other in a self-reinforcing and interdependent manner. The intertwined nature of these factors may be overlooked when investigating impacts...
8.
Jalleh R, Marathe C, Rayner C, Jones K, Umapathysivam M, Wu T, et al.
Endocrinology
. 2024 Nov;
166(1).
PMID: 39568409
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as "GLP-1-based therapy") are incretin-based therapies being used increasingly in...
9.
Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum
Jalleh R, Jones K, Islam M, Cai L, Horowitz M
World J Diabetes
. 2024 Nov;
15(10):2036-2040.
PMID: 39493561
In this editorial, we comment on the article by He , specifically in relation to the efficacy of bariatric surgery glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in the management of...
10.
Jalleh R, Plummer M, Marathe C, Umapathysivam M, Quast D, Rayner C, et al.
J Clin Endocrinol Metab
. 2024 Oct;
110(1):1-15.
PMID: 39418085
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This...